Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review

Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review

Objective: The recent American Society of Clinical Oncology (ASCO) Clinical Guidelines for chemotherapy-induced peripheral neuropathy (CIPN) management (48 Phase III trials reviewed) only recommend duloxetine. However, before concluding that a CIPN intervention is ineffective, scientists and clinici...

Full description

Bibliographic Details
Main Authors: Deborah Lee, Grace Kanzawa-Lee, Robert Knoerl, Gwen Wyatt, Ellen M. Lavoie Smith
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Asia-Pacific Journal of Oncology Nursing
Subjects:
Cancer
chemotherapy-induced peripheral neuropathy
prevention
treatment
Online Access:http://www.apjon.org/article.asp?issn=2347-5625;year=2019;volume=6;issue=4;spage=318;epage=332;aulast=Lee

Internet

http://www.apjon.org/article.asp?issn=2347-5625;year=2019;volume=6;issue=4;spage=318;epage=332;aulast=Lee

Similar Items